Natural products targeting secondary pathological mechanisms in Duchenne muscular dystrophy: a scoping review
Year: 2026
Type: article
Study design: Systematic Review
Abstract: Duchenne muscular dystrophy (DMD) is caused by dystrophin deficiency and is accompanied by interconnected secondary pathological processes, including chronic inflammation, oxidative stress, impaired muscle regeneration, fibrosis, mitochondrial dysfunction, calcium dysregulation, and vascular dysfunction. Natural products have been investigated as experimental modulators of several of these processes, but the evidence is heterogeneous in intervention type, model, exposure, and outcome. A systematic search of PubMed, Scopus, Web of Science, ScienceDirect, and Cochrane Library (2015–2024) identified studies evaluating natural products (NPs) in DMD models. Data were analyzed focusing on the molecular mechanisms of action and pharmacological outcomes. Twenty-one primary studies met the DMD-specific criteria after two non-DMD-model reports were excluded from the initially charted 23 records. The eligible evidence was predominantly preclinical, with one small clinical pilot that included a DMD subgroup. Based on reconciled outcome charting, inflammation (12/21), oxidative stress (8/21), regeneration (12/21), fibrosis (10/21), and mitochondrial-related processes (4/21) were represented; these overlapping counts require final primary-paper verification. Direct compounds, complex formulations, delivery adjuncts, and ex vivo cell-expansion reagents were considered separately. The literature maps natural-product interventions to multiple secondary mechanisms relevant to DMD, but it remains predominantly preclinical and methodologically heterogeneous. The current evidence does not establish DMD-specific clinical efficacy, long-term safety, corticosteroid-sparing effects, or a role in standard care. Future work should use prospectively defined DMD models and outcomes, transparent pharmacokinetic and safety reporting, and adequately powered DMD-specific clinical studies.
Source: Skeletal Muscle
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,890
Award: G7084852683
OpenAlex ID: W7235837371
